2Morris LF,Ragavendra N,Yeh MW.Evidence-based assessment of the role of ultrasonography in the management of benign thyroid nodules[J].World J Surg,2008,32(7):1 253-1 263.
3Rossi ED,Straccia P,Palumbo M,et al.Diagnostic and Prognostic Role of HBME-1,Galectin-3,and β-Catenin in Poorly Differentiated and Anaplastic Thyroid Carcinomas[J].Appl Immunohistochem Mol Morphol,2013,21(4):351.
4Yang SI,Park KK,Kim JH.Papillary carcinoma arising from thyroglossal duct cyst with thyroid and lateral neck metastasis[J].Int J Surg Case Rep,2013,4(8):704-707.
5Som PM,Brandwein M,Lidov M,et al.The varied presentations of papillary thyroid carcinoma cervical nodal disease:CT and MRI findings[J].AJNR Am Neuroradiol,1994,15:1 123-1 128.
6Cooper DS,Doherty GM.Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J].Thyroid,2009,19 (11):1 167-1214.
7Romei C,Elisei R.RET/PTC Translocations and ClinicoPathological Features in Human Papillary Thyroid Carcinoma[J].Front Endocrinol (Lausanne),2012,3:54.
8Vasko V,Ferrand M,Di Cristofaro J,et al.Specific pattern of rasoncogene mutations in follicular thyroid tumors[J].J Clin Endocrinol Metab,2003,88:2 745-2 752.
9Liebner DA,Shah MH.Thyroid cancer:pathogenesis and target ed therapy.[J].Ther Adv Endocrinol Metab,2011,2 (5):173195.
10Jung CK,Little MP,Lubin JH,et al.The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations[J].J Clin Endocrinol Metab,2013,18:24 248 188.
